Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||18 Years and Over|
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
|Phase 1/Phase 2|
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Principal Investigator Affiliation||Anaveon AG|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Countries||Spain, Switzerland, United Kingdom|
The disease, disorder, syndrome, illness, or injury that is being studied.
|Advanced Solid Tumor, Adult Disease, Multiple Myeloma|
The purpose of this First-in-Human, open-label, dose escalation and expansion study is to assess the initial safety and efficacy profile of ANV419 intravenous infusion in patients with advanced solid tumours and multiple myeloma. Phase 1 will evaluate the safety and tolerability of ANV419 alone and to determine a suitable dose for Phase 2 development. Phase 2 will evaluate the preliminary efficacy and, the safest and best dose of ANV419 when used alone or together with established cancer treatment.
Experimental: ANV419 single agent, Q2W
Experimental: ANV419 in combination with CPI or Immunostimulatory agent, Q2W
Drug: - ANV419
ANV419 administered by intravenous (IV) infusion
Drug: - CPI or Immunostimulatory agent
CPI or other immunostimulatory administred per treatment modalities
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.